Data show favorable outcomes for angle-supported phakic IOL

Minneapolis-Results from 3 years of follow-up in the FDA phase II clinical trial investigating an angle-supported phakic IOL (AcrySof Cachet, Alcon Laboratories) for the treatment of moderate to high myopia indicate this anterior chamber implant provides excellent visual acuity and is associated with accurate predictability of refraction and promising safety, said Stephen S. Lane, MD.

"So far, the results with [this lens] are encouraging in showing that it has avoided some of the concerns that have plagued previous anterior chamber phakic IOLs," Dr. Lane said.

Refractive outcomes showed good stability over time and excellent predictability. With 46 eyes evaluated at 3 years, MRSE averaged –0.21 ± 0.47 D, was within 0.5 D of intended in 85% of eyes, and within 1 D in 93.5% of eyes.

Consistent with the refractive results, uncorrected visual acuity (UCVA) outcomes were excellent. At 3 years, mean logMAR UCVA was 0.03 ± 0.18, 83% of eyes achieved UCVA of 20/25 or better, and 95% could see 20/40 or better.

"Phakic IOLs in general and this lens in particular provide an outstanding 'wow' factor," Dr. Lane said.

Best spectacle-corrected visual acuity (BSCVA) was 20/25 or better in all eyes, and mean logMAR BSCVA was –0.12 ± 0.07 D at 3 years.

"We've typically seen improvements in BSCVA with most phakic IOLs, and the angle-supported IOL was no exception," Dr. Lane said. "At 3 years, almost 50% of patients gained 1 line, about 10% achieved an improvement of 2 or more lines, and no patients had any loss of BSCVA."